January 8, 2018 / 2:16 PM / 8 months ago

BRIEF-Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement

Jan 8 (Reuters) - Resverlogix Corp:

* RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT

* RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​

* RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION

* RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO'S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY

* RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below